Sangamo therapeutics, inc. (SGMO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

13,076

54,851

21,958

17,548

8,071

26,837

23,562

21,416

12,637

13,077

11,812

8,253

3,425

8,922

2,823

3,702

3,942

9,121

8,569

8,358

13,491

14,952

12,417

10,385

8,116

6,869

5,707

6,934

4,623

8,932

4,907

4,574

3,242

4,748

1,857

1,514

2,200

2,943

6,525

Operating expenses:
Research and development

41,479

38,329

36,288

36,455

34,850

33,254

28,810

29,255

23,547

19,377

18,425

14,984

12,942

13,890

17,008

19,454

15,266

19,906

16,694

15,618

14,980

15,091

16,340

13,460

12,083

10,838

8,703

9,278

8,220

9,282

7,570

7,574

7,283

7,878

7,839

8,119

8,262

8,769

7,147

General and administrative

16,119

15,053

14,918

14,597

17,118

14,355

10,993

11,301

10,087

7,466

6,422

6,037

7,275

4,862

5,021

11,090

5,357

4,888

4,560

5,017

4,732

4,330

3,731

3,972

3,644

4,205

3,163

3,124

3,308

3,019

3,139

2,744

3,242

3,235

3,592

3,676

3,539

2,889

3,257

Total operating expenses

57,598

53,382

51,206

51,052

51,968

47,609

39,803

40,556

33,634

26,843

24,847

21,021

20,217

18,752

22,029

30,544

20,623

24,794

21,254

20,635

19,712

19,421

20,071

17,432

15,727

15,043

11,866

12,402

11,528

12,301

10,709

10,318

10,525

11,113

11,431

11,795

11,801

11,658

10,404

Loss from operations

-44,522

1,469

-29,248

-33,504

-43,897

-20,772

-16,241

-19,140

-20,997

-13,766

-13,035

-12,768

-16,792

-9,830

-19,206

-26,842

-16,681

-15,673

-12,685

-12,277

-6,221

-4,469

-7,654

-7,047

-7,611

-8,174

-6,159

-5,468

-6,905

-3,369

-5,802

-5,744

-7,283

-6,365

-9,574

-10,281

-9,601

-8,715

-3,879

Interest and other income, net

1,548

3,032

1,887

3,148

1,694

1,553

3,398

2,500

810

675

681

277

160

219

238

243

187

25

101

151

154

150

109

66

39

30

14

18

20

-

12

16

15

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,968

-26,599

-

-15,648

-12,584

-12,126

-6,067

-4,319

-7,545

-6,981

-7,572

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit from income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-24

-

-1,635

-3,339

0

-748

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-42,974

4,501

-27,361

-30,356

-42,203

-19,219

-12,843

-16,640

-20,187

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to non-controlling interest

-61

-54

-54

-72

-53

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

20

22

23

20

19

Net loss to Sangamo Therapeutics, Inc. stockholders

-42,913

4,555

-27,307

-30,284

-42,150

-18,664

-12,843

-16,640

-20,187

-13,091

-12,354

-12,491

-16,632

-9,624

-18,965

-26,575

-16,494

-14,013

-9,245

-12,126

-5,319

-4,319

-7,545

-6,981

-7,572

-8,144

-6,145

-5,450

-6,885

-3,478

-5,790

-5,728

-7,268

-6,359

-9,554

-10,259

-9,578

-8,695

-3,860

Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)

-0.37

0.04

-0.24

-0.26

-0.41

-0.17

-0.13

-0.17

-0.23

-0.15

-0.15

-0.17

-0.23

-0.14

-0.27

-0.38

-0.23

-0.20

-0.13

-0.17

-0.08

-0.06

-0.11

-0.10

-0.12

-0.14

-0.11

-0.10

-0.13

-0.06

-0.11

-0.11

-0.14

-0.12

-0.18

-0.20

-0.21

-0.19

-0.09

Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)

116,060

116,094

115,710

114,382

102,270

102,438

101,725

97,267

86,334

85,034

83,750

72,527

71,025

70,734

70,618

70,487

70,373

70,169

69,892

69,684

69,283

68,679

68,230

67,980

63,199

61,947

54,786

53,786

53,377

52,972

52,768

52,657

52,567

52,623

52,464

51,500

45,461

45,201

45,157

Net loss

-42,913

4,555

-27,307

-30,284

-42,150

-18,664

-12,843

-16,640

-20,187

-13,091

-12,354

-12,491

-16,632

-

-18,965

-26,575

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,554

-10,259

-9,578

-8,695

-3,860

Changes in unrealized gain (loss) on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19

3

20

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,573

-10,256

-9,558

-

-

Collaboration Agreements [Member]
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

3,306

8,850

2,728

3,592

3,711

8,966

8,406

7,801

12,671

14,546

12,045

9,721

7,568

6,613

4,825

6,157

4,083

8,521

4,190

3,812

1,663

3,234

781

608

1,487

2,234

6,210

Research Grants [Member]
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

119

72

95

110

231

155

163

557

820

406

372

664

548

256

882

777

540

411

717

762

1,579

1,514

1,076

906

713

709

315